Literature DB >> 5818682

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.

R Alexanian, A Haut, A U Khan, M Lane, E M McKelvey, P J Migliore, W J Stuckey, H E Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5818682     DOI： 10.1001/jama.208.9.1680

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  85 in total

Review 1.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

2.  Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?

Authors:  S El Mahou; M Attal; B Jamard; A Constantin; A Cantagrel; B Mazières; C Arnaud; M Laroche
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

Review 3.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

4.  A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.

Authors:  J Bladé; J San Miguel; A Alcalá; J Maldonado; J García-Conde; M J Moro; M A Sanz Sanz; C Alonso; A Zubizarreta; C Besses
Journal:  Blut       Date:  1990-06

5.  Electrophoretic study of the physico-chemical characteristics of Bence-Jones proteinuria and its association with kidney damage.

Authors:  M C Diemert; L Musset; O Gaillard; S Escolano; A Baumelou; F Rousselet; J Galli
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

6.  Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.

Authors:  D E Bergsagel; D H Cowan; R Hasselback
Journal:  Can Med Assoc J       Date:  1972-11-04       Impact factor: 8.262

Review 7.  Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Vincent S Rajkumar
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

8.  Clinical manifestations of multiple myeloma: relation to class and type M component.

Authors:  W Pruzanski
Journal:  Can Med Assoc J       Date:  1976-05-22       Impact factor: 8.262

9.  Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.

Authors:  A Solomon; C L McLaughlin; J D Capra
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

10.  Front line treatment of elderly multiple myeloma in the era of novel agents.

Authors:  Marie-Dominique Venon; Aldo M Roccaro; Julie Gay; Anne-Sophie Moreau; Remy Dulery; Thierry Facon; Irene M Ghobrial; Xavier Leleu
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.